Vendor, New Haven, CT
L2 Diagnostics LLC
UEI GKA7VH5LFR25, CAGE 43BA5
2 awards and $899,471 obligated between December 3, 2024 and July 22, 2026, 100% under full and open competition, against 6.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 2 |
Hear when L2 Diagnostics LLC wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts L2 Diagnostics LLC holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $599,471
- Soonest
- July 31, 2027
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,369,442 |
| Westat, Inc.Rockville, MD | $760,724,225 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,758,507 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93025C00024Definitive Contract, July 28, 2025, Full and Open Competition After Exclusion of Sources, 9 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Therapeutic Vaccine Platform to Boost Immune Responses in TuberculosisNAICS 541715, PSC AN11 | $599,471 |
| 75N93025C00004Definitive Contract, December 3, 2024, Full and Open Competition After Exclusion of Sources, 3 offers | National Institutes of Health NiaidNational Institutes of Health | Novel Diagnostic Biomarkers Discovery and Validation for Malaria SBIR Phase INAICS 541714, PSC AN12 | $300,000 |
- Places of performance
- Connecticut
- Product and service codes
- AN11 Health R&D Services; Health Care Services; Basic ResearchAN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 5 across 2 awards